Clinical trial
Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young…
NCT00089349 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00089349 |
|---|---|
| Title | Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia |
| Official title | A Phase II Study of Campath-1H in Children With Acute Lymphoblastic Leukemia in Second or Greater Relapse or Twice Induction Failure |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Childhood Acute Lymphoblastic Leukemia |
| Intervention type | Biological, Drug |
| Interventions | alemtuzumab, methotrexate, mercaptopurine |
| Enrollment | 25 |
| Start date | Jul 1, 2004 |
| Primary completion | Sep 1, 2006 |
| First posted | Aug 5, 2004 |
| Last update posted | Jun 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: